Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
$1.95
$2.17
$1.50
$6.48
$13.83M1.387,484 shsN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$8.15
+2.1%
$8.39
$5.01
$10.75
$10.25M0.8812,433 shs1,817 shs
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
$1.57
+1.3%
$1.51
$0.62
$2.50
$25.46M2.36145,315 shs50,845 shs
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$1.15
$1.06
$0.45
$1.68
$57.22M1.57.44 million shs15.01 million shs
resTORbio, Inc. stock logo
TORC
resTORbio
$1.88
-10.9%
$12.16
$0.86
$10.50
$68.35M2.431.15 million shs1.48 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
0.00%0.00%0.00%0.00%0.00%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
+3.16%+1.24%-9.55%+42.98%+35.83%
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
+1.29%+9.79%+0.64%-8.72%+57.00%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00%0.00%0.00%0.00%0.00%
resTORbio, Inc. stock logo
TORC
resTORbio
-10.71%-7.41%-16.29%-25.89%-68.22%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
1.2195 of 5 stars
3.53.00.00.00.60.00.6
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
resTORbio, Inc. stock logo
TORC
resTORbio
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
2.00
HoldN/AN/A
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
3.00
Buy$6.00282.17% Upside
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/A
resTORbio, Inc. stock logo
TORC
resTORbio
N/AN/AN/AN/A

Current Analyst Ratings

Latest ITRM, FWP, TORC, NEOS, and GHSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
3/6/2024
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
2/7/2024
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$6.00
2/2/2024
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/A$10.09 per shareN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.85$0.14 per share57.36$6.39 per share1.28
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.48) per shareN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$64.65M0.89N/AN/A($0.12) per share-9.58
resTORbio, Inc. stock logo
TORC
resTORbio
N/AN/AN/AN/A$2.24 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
-$1.89MN/A0.00N/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$0.1174.10N/A0.51%2.01%1.21%5/20/2024 (Estimated)
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
-$16.90M-$0.34N/AN/AN/A-38.35%N/A-28.46%N/A
resTORbio, Inc. stock logo
TORC
resTORbio
-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/A

Latest ITRM, FWP, TORC, NEOS, and GHSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A$0.33+$0.33$0.33N/A$21.56 million
3/28/2024Q4 2023
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
-$1.02-$0.94+$0.08-$0.94N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/A
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/A
resTORbio, Inc. stock logo
TORC
resTORbio
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/A
18.43
N/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
9.01
6.98
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
3.63
1.89
1.89
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/A
0.66
0.53
resTORbio, Inc. stock logo
TORC
resTORbio
N/A
20.69
20.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
12.57%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
20.21%
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
9.21%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
33.13%
resTORbio, Inc. stock logo
TORC
resTORbio
46.19%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
47.09 million2.02 millionNot Optionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
91.28 million1.27 millionNot Optionable
Iterum Therapeutics plc stock logo
ITRM
Iterum Therapeutics
1416.43 million15.54 millionNot Optionable
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
21349.76 millionN/AOptionable
resTORbio, Inc. stock logo
TORC
resTORbio
N/A36.45 millionN/ANot Optionable

ITRM, FWP, TORC, NEOS, and GHSI Headlines

SourceHeadline
John FlynnJohn Flynn
fleetowner.com - April 24 at 4:23 PM
Adicet Bio Inc (ACET)Adicet Bio Inc (ACET)
investing.com - January 30 at 1:54 PM
Targeting the biology of aging with mTOR inhibitors - Nature.comTargeting the biology of aging with mTOR inhibitors - Nature.com
news.google.com - May 4 at 10:20 PM
PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLivePARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid ... - OncLive
news.google.com - March 17 at 7:14 PM
Michelle Chaka Joins Torc as Senior Vice President, Safety and RegulatoryMichelle Chaka Joins Torc as Senior Vice President, Safety and Regulatory
finance.yahoo.com - February 24 at 7:08 PM
Torc names regulatory, safety SVPTorc names regulatory, safety SVP
virginiabusiness.com - February 24 at 7:08 PM
Global AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPRGlobal AI in Life Extension Market Poised for Growth Amidst Rising Demand for Prolonging Life (2022 - 2030) - openPR
news.google.com - February 8 at 10:13 AM
Phenotypic Presentations and the Management of Moderate to ... - HealioPhenotypic Presentations and the Management of Moderate to ... - Healio
news.google.com - January 31 at 2:37 PM
Aerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.comAerovate Therapeutics Appoints Donald Santel To Its Board of ... - Marketscreener.com
news.google.com - January 23 at 3:41 PM
Aerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswireAerovate Therapeutics Appoints Donald Santel To Its Board of ... - GlobeNewswire
news.google.com - January 23 at 8:44 AM
TinOne Resources Inc. (TORC.V)TinOne Resources Inc. (TORC.V)
finance.yahoo.com - January 10 at 8:39 AM
resTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities NewsresTORbio IPO on Deck, Less than a Year After Licensing Clinical ... - Equities News
news.google.com - December 16 at 11:48 PM
resTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities NewsresTORbio Shows Positive Phase 2b Data in Respiratory Tract Infections - Equities News
news.google.com - December 12 at 10:01 PM
Brian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.TechnologyBrian Kennedy – validating aging interventions and why rapamycin is the gold standard - Longevity.Technology
news.google.com - November 3 at 9:25 PM
TORC Investments, LLCTORC Investments, LLC
gwinnettdailypost.com - October 6 at 9:57 AM
Celebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - ForbesCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbes
forbes.com - September 19 at 2:52 PM
Fast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business JournalsFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business Journals
bizjournals.com - September 12 at 7:31 PM
Cellular Immunotherapy Market Study 2022-2030 by Current and Upcoming Trends, Opportunities, Size, Trends and - openPRCellular Immunotherapy Market Study 2022-2030 by Current and Upcoming Trends, Opportunities, Size, Trends and - openPR
openpr.com - September 6 at 7:33 AM
For preventing aging, some decades old drugs? - BioWorld OnlineFor preventing aging, some decades old drugs? - BioWorld Online
bioworld.com - July 18 at 10:42 PM
Form DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.com
streetinsider.com - July 8 at 2:10 AM
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.comTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.com
gurufocus.com - June 21 at 9:11 PM
The Best Hand Creams - Dont Waste Your MoneyThe Best Hand Creams - Don't Waste Your Money
dontwasteyourmoney.com - June 18 at 1:34 PM
Time Passages: Bruce Goldsmith out at Jim Wilsons gene therapy biotech; Flagship reveals Michael Severinos CEO gig - Endpoints NewsTime Passages: Bruce Goldsmith out at Jim Wilson's gene therapy biotech; Flagship reveals Michael Severino's CEO gig - Endpoints News
endpts.com - June 3 at 11:42 PM
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - KULR-TVTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - KULR-TV
kulr8.com - June 3 at 11:42 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Forward Pharma A/S logo

Forward Pharma A/S

NASDAQ:FWP
Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.
Guardion Health Sciences logo

Guardion Health Sciences

NASDAQ:GHSI
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
Iterum Therapeutics logo

Iterum Therapeutics

NASDAQ:ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Neos Therapeutics logo

Neos Therapeutics

NASDAQ:NEOS
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.
resTORbio logo

resTORbio

NASDAQ:TORC
Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.